Universal Lysis Buffer for Respiratory Sample Processing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for respiratory diseases, such as pneumonia, are inefficient and labor-intensive, requiring different handling procedures for various bodily samples, leading to contamination risks and inability to perform high-throughput molecular diagnostics.
Innovation Solution
A universally applicable lysis buffer containing a chaotropic agent, a reducing agent, and a protease, along with a processing method that allows for complete lysis in a single reaction tube without centrifugation or sample transfer, enabling direct nucleic acid isolation and reducing contamination risks.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If different lysis buffers and processing methods are used for each sample type, then lysis efficiency for specific sample types is improved, but device complexity and ease of operation deteriorate due to multiple protocols
Solution Approach 1:
The patent develops a universal lysis buffer composition and processing method that can be applied to all sample types relevant for molecular diagnostics of respiratory diseases (sputum, blood, pleural fluid, bronchoalveolar lavage, tracheal aspirate, nasopharyngeal swabs). This single protocol replaces multiple sample-type-specific protocols, reducing complexity while maintaining reliability across all sample types.
2Measurement precision
If laborious decontamination and liquefaction procedures are used, then pathogen detection accuracy is improved, but productivity and ease of operation deteriorate
Solution Approach 1:
The patent combines decontamination, liquefaction, and lysis steps into a single integrated processing procedure. The universal lysis buffer performs multiple functions simultaneously: it decontaminates samples, liquefies viscous materials, and lyses cells to release nucleic acids. This eliminates the need for separate laborious steps, increasing productivity while maintaining pathogen detection accuracy.
Solution Approach 2:
The lysis buffer is designed to perform preliminary decontamination and liquefaction actions before nucleic acid extraction. By pre-treating samples with the universal lysis buffer, the method prepares samples in advance for direct nucleic acid isolation without requiring additional intermediate processing steps.
3Manufacturing precision
If extensive sample processing and transfer steps are performed, then nucleic acid isolation quality is improved, but contamination risk increases
Solution Approach 1:
The patent combines all processing steps (decontamination, liquefaction, lysis) and nucleic acid isolation into a single reaction tube. By eliminating multiple transfer steps between different tubes and equipment, the method significantly reduces contamination risk while maintaining nucleic acid isolation quality through the optimized universal lysis buffer composition.
4Reliability
If sample viscosity is reduced through extensive processing, then pathogen accessibility is improved, but loss of time and productivity increase
Solution Approach 1:
The universal lysis buffer contains components that perform preliminary liquefaction and viscosity reduction actions directly on the sample. This pre-treatment makes pathogens accessible without requiring extended processing times, as the buffer composition is specifically designed to rapidly break down viscous materials while maintaining pathogen integrity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The solution enables efficient and safe lysis of diverse bodily samples, facilitating high-throughput molecular diagnostics for respiratory diseases by reducing labor and contamination, and allowing for direct nucleic acid analysis without extensive pre-treatment.
Implementation Method 1
a lysis buffer comprising (i) at least one chaotropic agent, (ii) at least one reducing agent, and (iii) at least one proteolytic enzyme
Implementation Method 2
a lysis buffer comprising (i) at least one chaotropic agent, (ii) at least one reducing agent, and (iii) at least one proteolytic enzyme
Implementation Method 3
a lysis buffer comprising (i) at least one chaotropic agent, (ii) at least one reducing agent, and (iii) at least one proteolytic enzyme
Data Source
AI summary
The present invention provides a universally applicable lysis buffer comprising a chaotropic 5 agent, a reducing agent, and a proteolytic enzyme suitable for processing a wide variety of different sample types, such as different types of bodily samples relevant for the diagnosis of a respiratory disease. Furthermore, the present invention provides the use of a chaotropic agent, a reducing agent, and a proteolytic enzyme for the lysis of a broad spectrum of bodily samples. Moreover, the present invention provides a method for processing bodily samples which is universally applicable to the lysis of a variety of different types of bodily samples. Furthermore, the present invention provides methods for analyzing a bodily sample or for detecting the presence of a pathogen in a bodily sample, preferably, for diagnosing a respiratory disease, such as pneumonia or tuberculosis. Preferably, these methods are universally applicable to a variety of sample types, are applicable as one-tube-processes, are 15 suitable for performance in a high-throughput setting, and are automatable.